TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

QURE INVESTIGATION: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Kessler Topaz Meltzer & Check, Llp
QURE INVESTIGATION: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

uniQure received FDA notification that its gene therapy data for AMT-130 does not sufficiently support a Biologics License Application for Huntington's disease treatment, causing significant stock price decline.

Insights
QURE   negative

Stock price dropped over 50% after FDA indicated insufficient evidence for Biologics License Application, suggesting potential regulatory and financial challenges for the company's gene therapy treatment